PublisherInfo				
PublisherName		BioMed Central		
PublisherLocation		London		
PublisherImprintName		BioMed Central		

Arsenic and old telomerase

ArticleInfo		
ArticleID	:	4263
ArticleDOI	:	10.1186/gb-spotlight-20011127-01
ArticleCitationID	\Box	spotlight-20011127-01
ArticleSequenceNumber	\Box	334
ArticleCategory	:	Research news
ArticleFirstPage	:	1
ArticleLastPage	:	2
ArticleHistory	:	RegistrationDate : 2001–11–27 OnlineDate : 2001–11–27
ArticleCopyright	:	BioMed Central Ltd2001
ArticleGrants	:	
ArticleContext	:	130592211

Tudor Toma

Email: t.toma@ic.ac.uk

Although arsenic is effective in the treatment of acute promyelocytic leukaemia, it also has carcinogenic side effects, but the exact mode of action in carcinogenesis remains unclear. In the November Journal of Clinical Investigation, Wen-Chien Chou and colleagues from Johns Hopkins University School of Medicine, Baltimore, US show that, at clinically relevant doses, arsenic inhibits the transcription of the reverse-transcriptase subunit of the human telomerase gene (*hTERT*).

Chou *et al.* found that exposing NB4 leukemia cells to arsenic inhibited transcription of the *hTERT* gene by decreasing c-Myc and Sp1 transcription factor activities. Decreased *hTERT* activity led to chromosomal end lesions, which promoted either genomic instability and carcinogenesis or cancer cell death (*J Clin Invest* 2001, **108:**1541-1547).

"These results may explain the seemingly paradoxical carcinogenic and antitumor effects of arsenic", concluded Chou.

References

- 1. Chou W-C, Hawkins AL, Barrett JF, Griffin CA, Dang CV: Arsenic inhibition of telomerase transcription leads to genetic instability. *J Clin Invest* 2001, 108:1541-1547., [http://www.jci.org]
- 2. Johns Hopkins University School of Medicine, [http://www.hopkinsmedicine.org/medicalschool/]